Items where authors include "Miller, T.M."

Article

Miller, T.M., Cudkowicz, M.E., Shaw, P.J. et al. (428 more authors) (2025) Long-term tofersen in SOD1 amyotrophic lateral sclerosis. JAMA Neurology. ISSN 2168-6149

Miller, T.M., Cudkowicz, M.E., Genge, A. et al. (23 more authors) (2022) Trial of antisense oligonucleotide tofersen for SOD1 ALS. New England Journal of Medicine, 387 (12). pp. 1099-1110. ISSN 0028-4793

Dewan, R. orcid.org/0000-0002-7611-7032, Chia, R. orcid.org/0000-0002-4709-7423, Ding, J. et al. (469 more authors) (2021) Pathogenic huntingtin repeat expansions in patients with frontotemporal dementia and amyotrophic lateral sclerosis. Neuron, 109 (3). 448-460.e4. ISSN 0896-6273

Reichenstein, I., Eitan, C., Diaz-Garcia, S. et al. (42 more authors) (2019) Human genetics and neuropathology suggest a link between miR-218 and amyotrophic lateral sclerosis pathophysiology. Science Translational Medicine, 11 (523). eaav5264. ISSN 1946-6234

Proceedings Paper

Miller, T.M., Cudkowicz, M.E., Shaw, P.J. orcid.org/0000-0002-8925-2567 et al. (9 more authors) (2025) Final results from the phase 3 VALOR trial and open-label extension evaluating efficacy and safety of tofersen in adults with SOD1-ALS. In: Muscle & Nerve. 24th Annual Meeting of the Northeast ALS Consortium, 07-10 Oct 2025, Florida, USA. , S97-S97.